Arbutus Biopharma Corp (ABUS) ລາຄາຮຸ້ນ ແລະ ຂ່າວ

ໜ້າທຳອິດABUS • NASDAQ

Arbutus Biopharma Corp

$4,26

16 ມ.ນ., 8 ໂມງ 20 ນາທີ 34 ວິນາທີ GMT-4 · USD · NASDAQ · ຂໍ້ຈຳກັດຄວາມຮັບຜິດຊອບ

ຮຸ້ນຫຼັກຊັບທີ່ມີລາຍຊື່ໃນ ສະຫະລັດສໍານັກງານໃຫຍ່ຕັ້ງຢູ່ ສະຫະລັດ

ປິດກ່ອນໜ້າ

$4,26

ຂອບເຂດລາຄາໃນປີ

$2,71 - $5,10

ມູນຄ່າຮຸ້ນຕາມລາຄາຕະຫຼາດ

819,30 ລ້ານ USD

ປະລິມານສະເລ່ຍ

2,67 ລ້ານ

ອັດຕາ P/E

ເງິນປັນຜົນ

ຕະຫຼາດຂັ້ນຕົ້ນ

NASDAQ

ຂ່າວຕະຫຼາດ

Yahoo Finance

17 ນາທີກ່ອນ

JFB (NASDAQ: JFB) Announces XTEND and Rayonix Execute Exclusive Manufacturing and Distribution Agreement with Initial $11 Million Commitment to Expand XOS Platform into India.

Fresno Bee

38 ນາທີກ່ອນ

New to The Street Broadcasts Episode Featuring FreeCast (NASDAQ:CAST), KLED.AI, PetVivo (OTCQB:PETV), EmpowerLit, and BlackBarn NYC on Bloomberg Television - March 21 at 6:30 PM EST

Quipt Home Medical (NASDAQ: QIPT) delists common shares via Form 25

Trump has 15 days to end the Iran war or markets face a brutal April repricing — from oil to the S&P 500

Severe oil shock could drag S&P 500 down to 5,400, Goldman warns

How do companies get added to (& dropped from) the Dow? The averages committee explained

.DJI

0,00%

ກ່ຽວກັບ

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia

CEO

William H. Collier

ສ້າງຕັ້ງ

2007

ສໍານັກງານໃຫຍ່

Warminster Township, ເພນຊີນວາເນຍ
ສະຫະລັດ

ເວັບໄຊ

arbutusbio.com

ພະນັກງານ